Narcolepsy market expected to reach $7.8bn across 7MM by 2035
With an estimated $4.4bn in drug sales, the US dominated the narcolepsy market in 2025, representing 97% of 7MM sales.
Comment & Opinion
ESC 2026: oral semaglutide shows lower 3-year CV risk than injectable in T2D
ESC 2026: Head-to-head study compares inclisiran and bempedoic acid
ESC 2026: enlicitide extends oral PCSK9 benefits beyond LDL-C lowering
ESC 2026: laroprovstat evaluated to close the LDL-C treatment gap
Surveillance and vaccine could protect against higher cancer risk from Lynch syndrome
US Executive Order 14420 and potential implications for diphtheria vaccination
AstraZeneca trips in PD-1 bispecific market after Phase III NSCLC failure
